Parkinson's disease: connecting mitochondria to inflammasomes.

Autor: Lawrence GMEP; Institute for Molecular Bioscience (IMB) Centre for Inflammation and Disease Research, University of Queensland, St Lucia, QLD, Australia., Holley CL; Institute for Molecular Bioscience (IMB) Centre for Inflammation and Disease Research, University of Queensland, St Lucia, QLD, Australia., Schroder K; Institute for Molecular Bioscience (IMB) Centre for Inflammation and Disease Research, University of Queensland, St Lucia, QLD, Australia. Electronic address: K.Schroder@imb.uq.edu.au.
Jazyk: angličtina
Zdroj: Trends in immunology [Trends Immunol] 2022 Nov; Vol. 43 (11), pp. 877-885. Date of Electronic Publication: 2022 Oct 11.
DOI: 10.1016/j.it.2022.09.010
Abstrakt: Activated microglia foster a neurotoxic, inflammatory environment in the mammalian central nervous system (CNS) that drives the pathology of neurodegenerative diseases including Parkinson's disease (PD). Moreover, mitochondrial fission promotes microglial inflammatory responses in vitro. Given that the NLRP3 inflammasome and mitochondria are central regulators of both inflammation and PD, we explore potential functions for the NLRP3 inflammasome and mitochondrial dynamics in PD. Specifically, we propose that inducible microglial mitochondrial fission can promote NLRP3-dependent neuroinflammation in hereditary and idiopathic PD. Further in-depth exploration of this topic can prompt valuable discoveries of the underlying molecular mechanisms of PD neuroinflammation, identify novel candidate anti-inflammatory therapeutics for PD, and ideally provide better outcomes for PD patients.
Competing Interests: Declaration of interests K.S. is a coinventor on patent applications for NLRP3 inhibitors which have been licensed to Inflazome Ltd, a company headquartered in Ireland, now acquired by Roche. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease. K.S. has served on the Scientific Advisory Board of Inflazome in 2016–2017, and serves as a consultant to Quench Bio, USA and Novartis, Switzerland. The other authors declare no conflicts of interest.
(Copyright © 2022 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: